Breakthrough science may capture the headlines, but in biotech, it's only the beginning of the story.

A promising therapy can produce encouraging clinical data, demonstrate meaningful patient benefit, and attract attention throughout the medical community. Yet none of those achievements alone determines whether that therapy will ultimately reach physicians and patients. The next stage is often just as important: building a regulatory strategy that turns scientific promise into an approved treatment.

For biotech companies, that process has become an increasingly important measure of execution. Clinical trial design, manufacturing readiness, regulatory engagement, and commercial planning are no longer viewed as separate milestones. Together, they represent the roadmap that determines whether promising research can successfully navigate the path toward commercialization.

That reality helps explain why experienced biotech investors often watch regulatory developments just as closely as they follow clinical results.

Oncolytics Biotech (NASDAQ: ONCY) provided a timely example this week.

The San Diego-based clinical-stage biotechnology company announced it has scheduled a Type D meeting with the U.S. Food and Drug Administration to discuss a potential registrational pathway for its REO 033 study in patients with RAS-mutant metastatic microsatellite-stable colorectal cancer (mCRC). The meeting will focus on adding a registration-directed Part B to the ongoing trial, creating a potential pathway that could support both accelerated approval and traditional approval within a single clinical program.

While discussions with the FDA do not guarantee future approvals, they often represent an important step in aligning a company's clinical strategy with regulatory expectations. For investors, they also provide insight into how management teams are thinking about long-term development, trial design, and commercialization.

For biotech companies, this stage of development often marks an important transition. Early clinical programs are designed to answer one fundamental question: does the science work? As programs mature, however, the focus expands well beyond efficacy. Companies must demonstrate they can design studies that satisfy regulators, manufacture therapies consistently, enroll appropriate patient populations, and execute development plans that support eventual approval. Strong science remains essential, but disciplined execution increasingly becomes part of the investment thesis.

The announcement builds on encouraging clinical data reported earlier this year.

In the company's REO 022 study evaluating  pelareorep in combination with FOLFIRI and bevacizumab in patients with metastatic colorectal cancer, KRAS-mutant patients achieved a median overall survival of 27.0 months, compared with approximately 11.2 months historically associated with standard treatment. Median progression-free survival reached 16.6 months, compared with approximately 5.7 months historically reported with standard care. While additional clinical development remains necessary, the findings have reinforced growing interest in immune-priming strategies designed to complement established cancer therapies rather than replace them.

Viewed together, the clinical data and the company's latest regulatory milestone suggest a broader strategy is taking shape. Rather than advancing promising science through a series of disconnected milestones, the company is integrating clinical development, regulatory planning, manufacturing readiness, and commercialization into a coordinated roadmap. As capital markets become more selective, the ability to execute consistently may prove just as valuable as the underlying scientific innovation.

That strategy is already being reflected in the company's operational execution.

According to the company, more than 20 patients have already been pre-identified for enrollment into the planned registration-directed portion of the REO 033 study, while approximately half of the participating clinical sites are expected to be activated during July. Those milestones suggest that planning for the study's next phase is already well underway, even as regulatory discussions continue.

For much of biotechnology's history, success was measured primarily by scientific discovery. Today, investors increasingly want to see something more: the ability to pair innovative science with disciplined execution. That means demonstrating not only promising clinical data, but also a clear regulatory strategy, operational readiness, and a credible path toward commercialization.

While clinical work remains ahead, Oncolytics' recent progress reflects a broader industry reality that others may want to follow: scientific innovation may open the first door, but strategic execution will likely determine how far that innovation ultimately travels.